Figure 8 Investment Strategies LLC purchased a new stake in shares of Versigent (NYSE:VGNT – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 16,305 shares of the company’s stock, valued at approximately $685,000.
Other large investors have also made changes to their positions in the company. Wellington Management Group LLP bought a new position in shares of Versigent in the second quarter worth about $940,000. Ancora Advisors LLC bought a new stake in Versigent during the 2nd quarter valued at approximately $4,197,000. Kintegral Advisory LLC purchased a new position in Versigent in the 2nd quarter worth approximately $224,000. Nan Shan Life Insurance Co. Ltd. purchased a new position in Versigent in the 2nd quarter worth approximately $5,400,000. Finally, Raiffeisen Bank International AG purchased a new position in Versigent in the 2nd quarter worth approximately $1,182,000.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on VGNT shares. TD Cowen increased their price objective on shares of Versigent from $49.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Fox Advisors downgraded shares of Versigent from an “overweight” rating to an “equal weight” rating in a report on Wednesday, August 5th. UBS Group dropped their target price on shares of Versigent from $58.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, July 9th. Evercore reaffirmed an “outperform” rating and set a $65.00 target price on shares of Versigent in a research note on Monday, August 10th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $59.00 price target on shares of Versigent in a report on Wednesday, August 5th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Versigent presently has an average rating of “Moderate Buy” and an average price target of $54.00.
Versigent Trading Up 3.7%
Shares of Versigent stock opened at $50.21 on Friday. The company’s 50 day moving average price is $43.75. Versigent has a 12 month low of $26.34 and a 12 month high of $50.88. The company has a market capitalization of $3.56 billion and a price-to-earnings ratio of 26.15. The company has a debt-to-equity ratio of 7.29, a quick ratio of 1.09 and a current ratio of 1.40.
Versigent (NYSE:VGNT – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.34. The firm had revenue of $2.44 billion during the quarter, compared to the consensus estimate of $2.29 billion. As a group, equities research analysts forecast that Versigent will post 7.23 earnings per share for the current fiscal year.
Versigent Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 18th. Investors of record on Friday, September 4th will be issued a $0.13 dividend. The ex-dividend date of this dividend is Friday, September 4th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.0%.
Versigent Profile
Versigent PLC is involved in the design, manufacturing and delivery of low and high voltage power electrical architectures. Versigent PLC is based in SCHAFFHAUSEN, Switzerland.
See Also
- Five stocks we like better than Versigent
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Want to see what other hedge funds are holding VGNT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versigent (NYSE:VGNT – Free Report).
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
